Aller au contenu principal
Profil bibliographique

CM Sassu

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

4Publications signalées
0Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Endometrial and Cervical Cancer TreatmentsAdvanced Breast Cancer TherapiesCancer Immunotherapy and BiomarkersOvarian cancer diagnosis and treatmentHER2/EGFR in Cancer Research

Les publications récentes

Accès ouvert 2026 article OpenAlex

35P Real-world impact of pembrolizumab-based chemoimmunotherapy in recurrent or metastatic cervical cancer: A large retrospective single-center series

I. Ruscito, M. Marraffa, E. Palluzzi, A. Cefaliello et autres

Metastatic and recurrent cervical cancer remains associated with poor prognosis. The KEYNOTE-826 trial established a new standard of care combining the checkpoint inhibitor pembrolizumab with platinum-based chemotherapy, with or without bevacizumab. We evaluated the efficacy and tolerability of this combination in a …

it (code pays fourni par la source)

0 citations ESMO Open
Accès ouvert 2026 article OpenAlex

154P Ocular toxicity related to mirvetuximab soravtansine in ovarian cancer: A real-world analysis

A. Giustozzi, F. De Dominicis, T. Salgarello, M. Cocuzza et autres

Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRα), approved for the treatment of patients with FRα-positive platinum-resistant ovarian cancer. Ocular adverse events are common with MIRV and may require dose modifications. Real-world data on incidence, predictors and clinical …

it (code pays fourni par la source)

0 citations ESMO Open
Accès ouvert 2026 article OpenAlex

33P Enhancing expert access and harmonising care pathways in rare gynaecological tumours across Europe: Real-world outcomes from the EURACAN G2 transnational virtual MDT 2023-2025

Gloria Marquina, A. Bergamini, Ulrika Joneborg, C. Lok et autres

Rare gynaecological tumours (RGTs) represent a highly heterogeneous group of malignancies, often with more limited clinical evidence and expertise in their management unevenly distributed across Europe. Evidence on optimal treatment is often limited, contributing to delayed diagnosis, suboptimal treatment, and unequal access …

es, it, se, nl, no, fr, gb, pl, fi, at, ro, be (code pays fourni par la source)

0 citations ESMO rare cancers.

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.